Clinical trials: Type 2 Diabetic
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
The purpose of this study is to see if GSK1292263 is safe and well-tolerated when administered to type 2 diabetics, and to get preliminary information about whether it may be effective in the treatment of type 2 diabetes.
- Trial name
- NCT01119846
- Testing
- GSK1292263, Sitagliptin
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic
The current study was to develop a software "Line@" based health education program, providing video-based health information and communication between diabetes patients and health-care professionals.
- Trial name
- NCT04876274
- Testing
- TMU-LOVE
- Where
- Taiwan
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 3 (NCT04795531)
- Testing
- Insulin icodec, Insulin degludec
- Where
- 190 sites in United States, Argentina and 10 more
- Volunteers
- 588 people
- Sponsor
- Novo Nordisk A/S
Asthma, Diabetes Mellitus
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Asthma
- Trial name
- NCT00139659
- Testing
- Inhaled Insulin, Subcutaneous Insulin
- Where
- 102 sites in United States, Brazil and 3 more
- Volunteers
- 288 people
- Sponsor
- Pfizer
Diabetes Mellitus, Chronic Kidney Disease
Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease
This study will assess the effects of vitamin D3 supplementation (cholecalciferol; 2000 IU daily) on serum calcium levels, circulating vitamin D levels, and markers of kidney disease and cardiovascular risk among people with…
- Conditions
- Diabetes Mellitus, Chronic Kidney Disease, Diabetic Kidney Disease
- Trial name
- NCT00552409
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Fatty Liver
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver
Non-alcoholic steatohepatitis (NASH), the most severe form of liver injury in the spectrum of non-alcoholic fatty liver disease (NAFLD), has emerged as the major cause of chronic liver disease in developed countries.
- Trial name
- NCT00323414
- Testing
- Polyunsaturated fatty acid (Opti-EPA)
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 2
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as…
- Trial name
- NCT01515657
- Testing
- PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- PLx Pharma
Diabetic Kidney Disease
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease
- Trial name
- NCT01752985
- Testing
- BMS-813160
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 319 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes
Evaluation of White Sweet Potato Tube Feeding Formula on Type 2 Diabetic Residents in Long-term Care Institutions
In order to response the increasing of aging population cause losing ability that need long-care needs, the project entitled "10-year long-term care program" from Executive Yuan in 2007 is carried out to assist economically…
- Trial name
- NCT02711839
- Testing
- Commercial diabetic formula, White sweet potato formula
- Volunteers
- 54 people
- Sponsor
- Taipei Medical University
Diabetes, Diabetes Mellitus, Type 2
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
This study is conducted in Europe. The aim of the study is to compare the effect of semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg once-daily on blood sugar levels after 30 weeks of…
- Trial name
- SUSTAIN 10 (NCT03191396)
- Testing
- Semaglutide, Liraglutide
- Where
- 92 sites in Bulgaria, Czechia and 10 more
- Volunteers
- 577 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Colesevelam for Children With Type 2 Diabetes
This study will evaluate the efficacy and safety of the study drug in treating type 2 diabetes in children 10 to 17 years old. The groups will be low-dose (0.625 g Welchol) and high-dose (3.75 g Welchol).
- Trial name
- WELKid DM (NCT01258075)
- Testing
- High-dose colesevelam, Low-dose colesevelam
- Where
- 24 sites in United States
- Volunteers
- 236 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus, Type 2, Endothelial Dysfunction
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes
Type 2 Diabetes Mellitus (T2DM) represents a model of endothelial dysfunction, where chronic nitric oxide deprivation, hyperglycaemia and hyperinsulinemia and fibrogenic mediators lead to cardiovascular remodelling associated…
- Trial name
- CECSID (NCT00692237)
- Testing
- Sildenafil
- Where
- Italy
- Volunteers
- 59 people
- Sponsor
- University of Roma La Sapienza
Diabetes Mellitus, Type 2
Effects of Qigong on Type 2 Diabetic Patients
Qigong therapy is a subtle energy-based methodology for preventing and healing diseases that has been practiced with remarkable results in China for about five thousand years.
- Trial name
- NCT00885846
- Testing
- Qigong therapy, Progressive resistance training
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Bastyr University
Type 2 Diabetes Mellitus, Vascular Disease
Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease
Aldosterone is a significant mediator of cardiovascular injury associated with heart failure and the cardiovascular benefits of mineralocorticoid receptor blockade are additive to those of angiotensin converting enzyme inhibitors…
- Trial name
- NCT00865124
- Testing
- Spironolactone, Hydrochlorothiazide + potassium
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Brigham and Women's Hospital
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes never treated with…
- Trial name
- BEGIN™ (NCT00982644)
- Testing
- insulin degludec, insulin glargine
- Where
- 187 sites in United States, Austria and 13 more
- Volunteers
- 1,030 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
The Revita™ System is being investigated to assess the ability to improve glycemic control in conjunction with diet and exercise in patients with Type 2 diabetes who are inadequately controlled with oral anti-diabetic…
- Trial name
- NCT03653091
- Testing
- Duodenal Mucosal Resurfacing (DMR)
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- Fractyl Health Inc.
Diabetes Mellitus, Type 2
A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients
The purpose is to evaluate the proportion of subjects achieving a Hemoglobin A1c (HbA1c) level below 6.5%, when lispro mix 50/50 is introduced in a stepwise manner from every day (QD) administration to type 2 diabetic patients…
- Trial name
- SIMPLE (NCT00971997)
- Testing
- Lispro Mix 50/50
- Where
- 14 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea
The purpose of this study is to evaluate safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not…
- Trial name
- NCT04980040
- Testing
- Alogliptin Benzoate
- Where
- 22 sites in South Korea
- Volunteers
- 3,623 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index [BMI] greater than or equal to 30 kilogram per…
- Trial name
- NCT00976937
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sitagliptin
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 319 people
- Sponsor
- Sanofi